Computational POM and DFT evaluation of experimental in-vitro cancer inhibition of staurosporine-ruthenium(II) complexes: The power force of organometallics in drug design
نوع المنشور
بحث أصيل
المؤلفون
النص الكامل
تحميل

A computational Petra/Osiris/Molinspiration/DFT(POM/DFT) based model has been developed for the identification of physico-chemical parameters governing the bioactivity of ruthenium-staurosporine complexes 2-4 containing an antitumoral-kinase (TK) pharmacophore sites. The four compounds 1-4 analyzed here were previously screened for their antitumor activity, compounds 2 and 4 are neutral, whereas analogue compound 3 is a monocation with ruthenium(II) centre. The highest anti-antitumor activity was obtained for compounds 3 and 4, which exhibited low IC50 values (0.45 and 8 nM, respectively), superior to staurosporine derivative (pyridocarbazole ligand 1, 150·103 nM). The IC50 of 3 (0.45 nM), represents 20,000 fold increased activity as compared to staurosporine derivative 1. The increase of bioactivity could be attributed to the existence of pi-charge transfer from metal-staurosporine to its (COδ-NHδ +) antitumor pharmacophore site.

المجلة
العنوان
Acta Chimica Slovenica
الناشر
Slovensko Kemijsko Drustvo
بلد الناشر
سلوفينيا
Indexing
Thomson Reuters
معامل التأثير
1,104
نوع المنشور
مطبوع فقط
المجلد
62
السنة
2015
الصفحات
679-688